1. Home
  2. ERNAW vs GOOGN Comparison

ERNAW vs GOOGN Comparison

Compare ERNAW & GOOGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ernexa Therapeutics Inc. Warrants

ERNAW

Ernexa Therapeutics Inc. Warrants

N/A

Current Price

$0.03

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Logo Alphabet Inc. Depositary Shares representing a 1/20th Interest in a Share of Series B Mandatory Convertible Preferred Stock

GOOGN

Alphabet Inc. Depositary Shares representing a 1/20th Interest in a Share of Series B Mandatory Convertible Preferred Stock

N/A

Current Price

$49.36

Market Cap

0.0

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ERNAW
GOOGN
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
198933
Industry
Computer Software: Programming Data Processing
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
ERNAW
GOOGN
Price
$0.03
$49.36
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.3K
783.4K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
31.29
34.45
EPS
N/A
14.24
Revenue
$582,000.00
$402,836,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.49
Revenue Growth
N/A
15.09
52 Week Low
$0.02
$46.23
52 Week High
$0.23
$52.82

Technical Indicators

Market Signals
Indicator
ERNAW
GOOGN
Relative Strength Index (RSI) 40.97 N/A
Support Level $0.03 N/A
Resistance Level $0.08 N/A
Average True Range (ATR) 0.02 0.00
MACD -0.00 0.00
Stochastic Oscillator 0.66 0.00

Price Performance

Historical Comparison
ERNAW
GOOGN

About ERNAW Ernexa Therapeutics Inc. Warrants

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

About GOOGN Alphabet Inc. Depositary Shares representing a 1/20th Interest in a Share of Series B Mandatory Convertible Preferred Stock

Alphabet is a holding company that wholly owns internet giant Google. The California-based company derives slightly less than 90% of its revenue from Google services, the vast majority of which is advertising sales. Alongside online ads, Google services houses sales stemming from Google's subscription services (YouTube TV and YouTube Music, among others), platforms (sales and in-app purchases on Play Store), and devices (Chromebooks, Pixel smartphones, and smart home products such as Chromecast). Google's cloud computing platform accounts for roughly 10% of Alphabet's revenue. The firm's investments in up-and-coming technologies such as self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.

Share on Social Networks: